Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Benjamin Eckert"'
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:HSR23-121
Publikováno v:
Blood. 140:13102-13104
Publikováno v:
Oncology and Therapy. 9:607-619
The measurement of minimal residual disease (MRD) with clonoSEQ® can be used in the assessment of B-cell lymphoid tumor burden throughout treatment with accuracy, sensitivity and standardization when compared to traditional cytomorphology. With the
Publikováno v:
Abstracts of the 26th Annual Meeting of the GCMAS.
Publikováno v:
Oncology and Therapy
Introduction The measurement of minimal residual disease (MRD) with clonoSEQ® can be used in the assessment of B-cell lymphoid tumor burden throughout treatment with accuracy, sensitivity and standardization when compared to traditional cytomorpholo
Publikováno v:
Blood. 138:3783-3783
Introduction Achieving minimal residual disease (MRD) negativity in multiple myeloma (MM) is positively correlated with prolonged PFS and OS (Landgren 2016, Munshi 2017), and longitudinal assessment of MRD can provide additional prognostication (Diam
Autor:
Tony Hewitt, Benjamin Eckert, Audrey Demaree, Josh J. Carlson, Ajay K. Nooka, Marita Zimmermann
Publikováno v:
Blood. 136:25-26
Background: The availability of standardized MRD assessment tools which meet clinical guideline requirements for minimum 10-5 sensitivity have been acknowledged by the International Myeloma Working Group (IMWG) and MRD assessment has been increasingl
Autor:
Benjamin Eckert, Fabian Eckert
In nur fünf Wochen das eigene Leben nachhaltig umkrempeln? Nichts leichter als das! … zumindest, wenn man einen Begleiter wie diesen hat: mit seinen 35 Tages- und 5 Wochen-Challenges ist der Umstieg in ein ressourcenleichtes, klimaschonendes Leben
Publikováno v:
Value in Health. 23:S445
Publikováno v:
Journal of Clinical Oncology. 38:e19280-e19280
e19280 Background: MRD assessment has been increasingly incorporated into guidelines and routine care for patients (pts) with multiple myeloma (MM). It has been widely shown that pts who achieve deep MRD negativity (MRD-) have longer PFS/OS. Clinical